Research Article
Inflammatory Demyelinating Central Nervous System Diseases in Childhood: Clinical and Paraclinical Profiles in 133 Patients
Table 3
Disease-modifying drugs and immunosuppressant drugs.
| | | | % |
| | IFNβ-1a SC | 22 | 16.5 | | Azathioprine | 14 | 10.5 | | Glatiramer acetate | 11 | 8.3 | | IFNβ-1b | 8 | 6 | | IFNβ-1a IM | 6 | 4.5 | | DMD + Mitoxantrone | 2 | 1.5 | | Monthly IVMP + Mitoxantrone | 1 | 0.8 | |
Azathioprine + oral prednisolone | 1 | 0.8 | | DMD + Azathioprine | 1 | 0.8 | | Natalizumab | 1 | 0.8 | | Laquinimod | 1 | 0.8 | | Fingolimod | 1 | 0.8 |
|
|
DMD: disease-modifying drugs; IVMP: intravenous methylprednisolone.
|
